AbbVie says newly approved hepatitis C treatment costs $83,319
December 19, 2014 at 18:45 PM EST
Dec 19 (Reuters) - An AbbVie Inc spokeswoman on Friday said that the company's newly approved hepatitis C treatment will cost $83,319 for a 12-week course, coming in a bit below the price of competing treatments from Gilead Sciences Inc.